Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in persistent asthma (EXPEDITION)
NCT02573233Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2016
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Dupilumab with Placebo (2 arms). Primary endpoints: Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at 12 weeks, Change From Baseline in Mucin-Stained Area in the Bronchial Submucosa at 12 weeks and 4 more. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02573233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573233.